LOUISVILLE, CO--(Marketwired - November 17, 2016) - GlobeImmune, Inc. today provided an update on the Company's business:
In July 2016, GlobeImmune filed to voluntarily delist the Company's outstanding Common Stock from The NASDAQ Capital Market and deregistered the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Company also terminated the Company's reporting obligations under Sections 13(a) and 15(d) of the Exchange Act and deregistered its Common Stock under Section 12(g) of the Exchange Act. The Company is no longer required to file annual, periodic and current reports with the SEC or release any other information. The Company does not plan to publicly release any further information about its operations or business.
Contact Information:
GLOBEIMMUNE INVESTOR CONTACT:
Susan Noonan
S.A. Noonan Communications
T: 212-966-3650
susan@sanoonan.com